IGC Pharma (DE:IGS1)
FRANKFURT:IGS1
Total Valuation
IGC Pharma has a market cap or net worth of €24.99M. The enterprise value is €28.71M.
Market Cap€24.99M
Enterprise Value€28.71M
Share Statistics
IGC Pharma has 100,091,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding100,091,320
Owned by Insiders9.70%
Owned by Institutions0.22%
Financial Efficiency
IGC Pharma’s return on equity (ROE) is -1.07 and return on invested capital (ROIC) is -161.64%.
Return on Equity (ROE)-1.07
Return on Assets (ROA)-0.71
Return on Invested Capital (ROIC)-161.64%
Return on Capital Employed (ROCE)-1.62
Revenue Per Employee17.70K
Profits Per Employee-97.73K
Employee Count67
Asset Turnover0.13
Inventory Turnover1.31
Valuation Ratios
The current PE Ratio of IGC Pharma is ―. IGC Pharma’s PEG ratio is 0.17.
PE Ratio―
PS Ratio21.08
PB Ratio4.08
Price to Fair Value4.08
Price to FCF-4.09
Price to Operating Cash Flow-4.64
PEG Ratio0.17
Income Statement
In the last 12 months, IGC Pharma had revenue of 1.19M and earned -6.55M in profits. Earnings per share was -0.07.
Revenue1.19M
Gross Profit352.00K
Operating Income-10.20M
Pretax Income-6.55M
Net Income-6.55M
EBITDA-9.88M
Earnings Per Share (EPS)-0.07
Cash Flow
In the last 12 months, operating cash flow was -5.94M and capital expenditures -164.00K, giving a free cash flow of -6.11M billion.
Operating Cash Flow-5.94M
Free Cash Flow-6.11M
Free Cash Flow per Share-0.06
Dividends & Yields
IGC Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.56
52-Week Price Change-4.48%
50-Day Moving Average0.25
200-Day Moving Average0.28
Relative Strength Index (RSI)47.20
Average Volume (3m)1.02K
Important Dates
IGC Pharma upcoming earnings date is Jun 15, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateJun 15, 2026
Ex-Dividend Date―
Financial Position
IGC Pharma as a current ratio of 0.40, with Debt / Equity ratio of 0.00%
Current Ratio0.40
Quick Ratio0.18
Debt to Market Cap0.00
Net Debt to EBITDA0.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, IGC Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
IGC Pharma EV to EBITDA ratio is -2.51, with an EV/FCF ratio of -4.06.
EV to Sales20.90
EV to EBITDA-2.51
EV to Free Cash Flow-4.06
EV to Operating Cash Flow-4.17
Balance Sheet
IGC Pharma has €207.00K in cash and marketable securities with €0.00 in debt, giving a net cash position of €207.00K billion.
Cash & Marketable Securities€207.00K
Total Debt€0.00
Net Cash€207.00K
Net Cash Per Share<€0.01
Tangible Book Value Per Share<€0.01
Margins
Gross margin is 29.68%, with operating margin of -860.29%, and net profit margin of -552.11%.
Gross Margin29.68%
Operating Margin-860.29%
Pretax Margin-552.11%
Net Profit Margin-552.11%
EBITDA Margin-832.97%
EBIT Margin-860.29%
Analyst Forecast
The average price target for IGC Pharma is €4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€4.50
Price Target Upside1508.20% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―